Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study

OBJECTIVE DESIGN SETTING PARTICIPANTS INTERVENTION MAIN OUTCOME MEASURE RESULTS CONCLUSIONRifaximin may be useful as alternative or adjuvant therapy for grade I-III hepatic encephalopathy in patients with cirrhosis at a dose of 1200 mg/day. Eur J Gastroenterol Hepatol 12:203-208 © 2000 Lippincott Wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of gastroenterology & hepatology 2000-02, Vol.12 (2), p.203-208
Hauptverfasser:	Williams, Roger, James, Oliver F. W, Warnes, Thomas W, Morgan, Marsha Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Biological and medical sciences Digestive system Dose-Response Relationship, Drug Double-Blind Method Female Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - therapeutic use Hepatic Encephalopathy - drug therapy Humans London Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Rifamycins - administration & dosage Rifamycins - therapeutic use Rifaximin Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	OBJECTIVE DESIGN SETTING PARTICIPANTS INTERVENTION MAIN OUTCOME MEASURE RESULTS CONCLUSIONRifaximin may be useful as alternative or adjuvant therapy for grade I-III hepatic encephalopathy in patients with cirrhosis at a dose of 1200 mg/day. Eur J Gastroenterol Hepatol 12:203-208 © 2000 Lippincott Williams & WilkinsEuropean Journal of Gastroenterology & Hepatology 2000, 12:203-208
ISSN:	0954-691X 1473-5687
DOI:	10.1097/00042737-200012020-00012